bluuebunny/crossref_metadata_2025 huggingface dataset:
Knowledge, Attitude, and Practice of Physiotherapists in COVID-19 ICUs: A National Survey
Authors: Suresh Babu Nikitha , Pratap Singh Vijay , Shyam Krishnan K. , Prabhu Dattatray
Published: January 2024

Background. COVID-19 belongs to the beta-corona cluster that spreads enormously via aerosols. Physiotherapists must be knowledgeable about the symptoms, mode of transmission, risk mitigation strategies, and practice guidelines for COVID-19. Objective. This study aimed to assess physiotherapists’ knowledge of COVID-19 guidelines, their attitude toward this new evolving field, and their practice routines in India’s COVID-19 ICUs. Methods. It was a cross-sectional study. A total of 600 questionnaires were distributed through e-mail and WhatsApp to physiotherapists using Google Forms between February 2022 and January 2023. The questionnaires consisted of demographics and 23 questions in three sections about the knowledge, attitude, and practice of physiotherapists working in the COVID-19 ICU. Data analysis was carried out using Jamovi. Results. A total of 136 responses were obtained from 18 states of India. Of 136 participants, 89 were female (65.4%) and 47 were male (34.6%). The highest level of qualification was BPT (n = 69 (50.7%)), followed by MPT (n = 62 (45.6%)) and Ph.D. (3 (3.7%)). The knowledge about COVID-19 guidelines is fair. Only 21.3% of the physiotherapists received training before being deployed in COVID-19 ICUs, and the CARP protocol was well known by only as few as 10.3%. The criteria advised for close monitoring of patients during treatment was aware by 29.4%. Most physiotherapists have a good attitude toward treating COVID-19 patients; 70.63% strongly agree that physiotherapy is vital in these patients despite the risk of self-exposure, and 64.7% agree that physiotherapy should be initiated during all phases of COVID-19. Physiotherapists follow good practices for COVID-19 patients in the ICU, which is as per the guideline recommendation. Conclusion. Physiotherapists working in COVID-19 ICUs have a fair knowledge of the existing physiotherapy guidelines for COVID-19, and they exhibit good attitudes and practice patterns.
Supplementary Table S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Authors: Kesari Santosh , Wagle Naveed , Carrillo Jose A. , Sharma Akanksha , Nguyen Minhdan , Truong Judy , Gill Jaya M. , Nersesian Raffi , Nomura Natsuko , Rahbarlayegh Elnaz , Barkhoudarian Garni , Sivakumar Walavan , Kelly Daniel F. , Krauss Howard , Bustos Matias A. , Hoon Dave S.B. , Anker Lars , Singh Arun S. , Sankhala Kamalesh K. , Juarez Tiffany M.
Published: January 2024

Table S5. The top 38 cfmiRs that are commonly DE in chordoma vs normal plasma samples when comparing top 100 most detected, top 100 most significant, and top 100 with highest FC.
Supplementary Table S2 from Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Authors: Randon Giovanni , Nakamura Yoshiaki , Yaeger Rona , Lonardi Sara , Cremolini Chiara , Elez Elena , Nichetti Federico , Ghelardi Filippo , Nasca Vincenzo , Bergamo Francesca , Conca Veronica , Ros Javier , Bando Hideaki , Maddalena Giulia , Oldani Simone , Prisciandaro Michele , Raimondi Alessandra , Schrock Alexa B. , Agnelli Luca , Walch Henry , Yoshino Takayuki , Pietrantonio Filippo
Published: January 2024

Response to dual HER2 blockade in patients with PRESSING-HER2 alterations.
Supplementary Table S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Authors: Kesari Santosh , Wagle Naveed , Carrillo Jose A. , Sharma Akanksha , Nguyen Minhdan , Truong Judy , Gill Jaya M. , Nersesian Raffi , Nomura Natsuko , Rahbarlayegh Elnaz , Barkhoudarian Garni , Sivakumar Walavan , Kelly Daniel F. , Krauss Howard , Bustos Matias A. , Hoon Dave S.B. , Anker Lars , Singh Arun S. , Sankhala Kamalesh K. , Juarez Tiffany M.
Published: January 2024

Table S2. Individual listing of additional chordoma tissue samples collected for miR WTA.
Supplementary Figure S3 from Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Authors: Randon Giovanni , Nakamura Yoshiaki , Yaeger Rona , Lonardi Sara , Cremolini Chiara , Elez Elena , Nichetti Federico , Ghelardi Filippo , Nasca Vincenzo , Bergamo Francesca , Conca Veronica , Ros Javier , Bando Hideaki , Maddalena Giulia , Oldani Simone , Prisciandaro Michele , Raimondi Alessandra , Schrock Alexa B. , Agnelli Luca , Walch Henry , Yoshino Takayuki , Pietrantonio Filippo
Published: January 2024

Boxplot for HER2 CNV in resistant vs sensitive patients.
Supplementary Figure S2 from Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study
Authors: Randon Giovanni , Nakamura Yoshiaki , Yaeger Rona , Lonardi Sara , Cremolini Chiara , Elez Elena , Nichetti Federico , Ghelardi Filippo , Nasca Vincenzo , Bergamo Francesca , Conca Veronica , Ros Javier , Bando Hideaki , Maddalena Giulia , Oldani Simone , Prisciandaro Michele , Raimondi Alessandra , Schrock Alexa B. , Agnelli Luca , Walch Henry , Yoshino Takayuki , Pietrantonio Filippo
Published: January 2024

Kaplan Meier curves for PFS (panel A) and OS (panel B) in the overall study population.
Table S3 from Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma
Authors: Pan Minggui , Zhou Maggie Yuxi , Jiang Chen , Zhang Zheyang , Bui Nam Q. , Bien Jeffrey , Siy Amanda , Achacoso Ninah , Solorzano Aleyda V. , Tse Pamela , Chung Elaine , Thomas Sachdev , Habel Laurel A. , Ganjoo Kristen N.
Published: January 2024

Demographics of patients wt and mut Rb1.
Supplementary Table 1 from Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer
Authors: Li Jianxia , Hu Huabin , Qin Ge , Bai Fan , Wu Xianrui , Ke Haoxian , Zhang Jianwei , Xie Yuqian , Wu Zehua , Fu Yang , Zheng Hongbo , Gong Longlong , Xie Zhi , Deng Yanhong
Published: January 2024

Clinical characterization of the cohort and allocation for testing
Table S2 from Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma
Authors: Pan Minggui , Zhou Maggie Yuxi , Jiang Chen , Zhang Zheyang , Bui Nam Q. , Bien Jeffrey , Siy Amanda , Achacoso Ninah , Solorzano Aleyda V. , Tse Pamela , Chung Elaine , Thomas Sachdev , Habel Laurel A. , Ganjoo Kristen N.
Published: January 2024

Demographics of patients with wt and mut CDKN2A.
Supplementary Table S6 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis
Authors: Hu Jia , Hameed Meera R. , Agaram Narasimhan P. , Whiting Karissa A. , Qin Li-Xuan , Villano Anthony M. , O'Connor Rachael B. , Rozenberg Julian M. , Cohen Sonia , Prendergast Katherine , Kryeziu Sara , White Richard L. , Posner Mitchell C. , Socci Nicholas D. , Gounder Mrinal M. , Singer Samuel , Crago Aimee M.
Published: January 2024

Gene set enrichment analysis performed on RNA-seq from pre-treatment biopsies taken from patients on the placebo arm of ALLIANCE A091105.
Supplementary Table S5 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis
Authors: Hu Jia , Hameed Meera R. , Agaram Narasimhan P. , Whiting Karissa A. , Qin Li-Xuan , Villano Anthony M. , O'Connor Rachael B. , Rozenberg Julian M. , Cohen Sonia , Prendergast Katherine , Kryeziu Sara , White Richard L. , Posner Mitchell C. , Socci Nicholas D. , Gounder Mrinal M. , Singer Samuel , Crago Aimee M.
Published: January 2024

Genes with altered expression in DES9525 cells after treatment with PDGF-BB as compared to untreated cells as determined by RNA-seq.
Supplementary Table S3 from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis
Authors: Hu Jia , Hameed Meera R. , Agaram Narasimhan P. , Whiting Karissa A. , Qin Li-Xuan , Villano Anthony M. , O'Connor Rachael B. , Rozenberg Julian M. , Cohen Sonia , Prendergast Katherine , Kryeziu Sara , White Richard L. , Posner Mitchell C. , Socci Nicholas D. , Gounder Mrinal M. , Singer Samuel , Crago Aimee M.
Published: January 2024

Genes noted to be altered in DES9525 after CTNNB1 knockdown as identified by RNA-seq. Fold change is relative to expression in cells treated with scramble control.
Table S5 from Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
Authors: Ganju Vinod , Marx Gavin , Pattison Scott , Amaro-Mugridge Nancy B. , Zhao Jing-Ting , Williams Bryan R.G. , MacDiarmid Jennifer A. , Brahmbhatt Himanshu
Published: January 2024

Table S5: Patient Weight Analysis in the Evaluable Subset
Supplementary Table S8 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Authors: Ou Xiaomin , Zhai Ruiping , Wei Wenjun , Chen Jiaying , Ou Dan , Liao Tian , Xu Tingting , Zhu Yongxue , Wang Yulong , Huang Shenglin , Shi Rongliang , Wu Bin , Chen Tongzhen , Li Yuan , Yang Zhongyi , Zhou Changming , Liu Yuan , Jiang Ziting , Zeng Min , Liu Xin , Ji Dongmei , Ying Hongmei , Zhang Zhen , Hu Chaosu , Lu Xueguan , Ji Qinghai , He Xiayun , Wang Yu
Published: January 2024

The speech and swallowing score at different timepoints
Supplementary Table S6 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Authors: Ou Xiaomin , Zhai Ruiping , Wei Wenjun , Chen Jiaying , Ou Dan , Liao Tian , Xu Tingting , Zhu Yongxue , Wang Yulong , Huang Shenglin , Shi Rongliang , Wu Bin , Chen Tongzhen , Li Yuan , Yang Zhongyi , Zhou Changming , Liu Yuan , Jiang Ziting , Zeng Min , Liu Xin , Ji Dongmei , Ying Hongmei , Zhang Zhen , Hu Chaosu , Lu Xueguan , Ji Qinghai , He Xiayun , Wang Yu
Published: January 2024

Recurrence patterns and reasons for death (N=27)
Figure S1 from Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
Authors: Ganju Vinod , Marx Gavin , Pattison Scott , Amaro-Mugridge Nancy B. , Zhao Jing-Ting , Williams Bryan R.G. , MacDiarmid Jennifer A. , Brahmbhatt Himanshu
Published: January 2024

Figure S1: Anti-LPS measurement
Supplementary Table S9 from Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Authors: Murray Joseph C. , Sivapalan Lavanya , Hummelink Karlijn , Balan Archana , White James R. , Niknafs Noushin , Rhymee Lamia , Pereira Gavin , Rao Nisha , Weksler Benny , Bahary Nathan , Phallen Jillian , Leal Alessandro , Bartlett David L. , Marrone Kristen A. , Naidoo Jarushka , Goel Akul , Levy Benjamin , Rosner Samuel , Hann Christine L. , Scott Susan C. , Feliciano Josephine , Lam Vincent K. , Ettinger David S. , Li Qing Kay , Illei Peter B. , Monkhorst Kim , Scharpf Robert B. , Brahmer Julie R. , Velculescu Victor E. , Zaidi Ali H. , Forde Patrick M. , Anagnostou Valsamo
Published: January 2024

Supplementary Table S9. Summary of samples analyzed for TCR sequencing*
Supplementary Table S8 from Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Authors: Murray Joseph C. , Sivapalan Lavanya , Hummelink Karlijn , Balan Archana , White James R. , Niknafs Noushin , Rhymee Lamia , Pereira Gavin , Rao Nisha , Weksler Benny , Bahary Nathan , Phallen Jillian , Leal Alessandro , Bartlett David L. , Marrone Kristen A. , Naidoo Jarushka , Goel Akul , Levy Benjamin , Rosner Samuel , Hann Christine L. , Scott Susan C. , Feliciano Josephine , Lam Vincent K. , Ettinger David S. , Li Qing Kay , Illei Peter B. , Monkhorst Kim , Scharpf Robert B. , Brahmer Julie R. , Velculescu Victor E. , Zaidi Ali H. , Forde Patrick M. , Anagnostou Valsamo
Published: January 2024

Supplementary Table S8. Summary of Cox proportional hazards model for progression-free survival.
Supplementary Table S1 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Authors: Ou Xiaomin , Zhai Ruiping , Wei Wenjun , Chen Jiaying , Ou Dan , Liao Tian , Xu Tingting , Zhu Yongxue , Wang Yulong , Huang Shenglin , Shi Rongliang , Wu Bin , Chen Tongzhen , Li Yuan , Yang Zhongyi , Zhou Changming , Liu Yuan , Jiang Ziting , Zeng Min , Liu Xin , Ji Dongmei , Ying Hongmei , Zhang Zhen , Hu Chaosu , Lu Xueguan , Ji Qinghai , He Xiayun , Wang Yu
Published: January 2024

Representativeness of Study Participants
Supplementary Figure S5 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Authors: Ou Xiaomin , Zhai Ruiping , Wei Wenjun , Chen Jiaying , Ou Dan , Liao Tian , Xu Tingting , Zhu Yongxue , Wang Yulong , Huang Shenglin , Shi Rongliang , Wu Bin , Chen Tongzhen , Li Yuan , Yang Zhongyi , Zhou Changming , Liu Yuan , Jiang Ziting , Zeng Min , Liu Xin , Ji Dongmei , Ying Hongmei , Zhang Zhen , Hu Chaosu , Lu Xueguan , Ji Qinghai , He Xiayun , Wang Yu
Published: January 2024

Comparative Analysis of Peripheral Lymphocyte Subpopulations Before Treatment in the Sensitive and Resistant Groups
Supplementary Appendix S1 from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Authors: Ou Xiaomin , Zhai Ruiping , Wei Wenjun , Chen Jiaying , Ou Dan , Liao Tian , Xu Tingting , Zhu Yongxue , Wang Yulong , Huang Shenglin , Shi Rongliang , Wu Bin , Chen Tongzhen , Li Yuan , Yang Zhongyi , Zhou Changming , Liu Yuan , Jiang Ziting , Zeng Min , Liu Xin , Ji Dongmei , Ying Hongmei , Zhang Zhen , Hu Chaosu , Lu Xueguan , Ji Qinghai , He Xiayun , Wang Yu
Published: January 2024

Appendix 1-trial protocol
Table 1 from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Authors: Mehanna Hisham , Rapozo Davy , von Zeidler Sandra V. , Harrington Kevin J. , Winter Stuart C. , Hartley Andrew , Nankivell Paul , Schache Andrew G. , Sloan Philip , Odell Edward W. , Thavaraj Selvam , Hunter Keith D. , Shah Ketan A. , Thomas Gareth J. , Long Anna , Amel-Kashipaz Rasoul , Brown Rachel M. , Conn Brendan , Hall Gillian L. , Matthews Paul , Weir Justin , Yeo Yen , Pring Miranda , West Catharine M.L. , McCaul James , Golusinski Pawel , Sitch Alice , Spruce Rachel , Batis Nikolaos , Bryant Jennifer L. , Brooks Jill M. , Jones Terence M. , Buffa Francesca , Haider Syed , Robinson Max
Published: January 2024

Characteristics of the training and validation cohorts.
Supplementary Figure S5 from Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Authors: Murray Joseph C. , Sivapalan Lavanya , Hummelink Karlijn , Balan Archana , White James R. , Niknafs Noushin , Rhymee Lamia , Pereira Gavin , Rao Nisha , Weksler Benny , Bahary Nathan , Phallen Jillian , Leal Alessandro , Bartlett David L. , Marrone Kristen A. , Naidoo Jarushka , Goel Akul , Levy Benjamin , Rosner Samuel , Hann Christine L. , Scott Susan C. , Feliciano Josephine , Lam Vincent K. , Ettinger David S. , Li Qing Kay , Illei Peter B. , Monkhorst Kim , Scharpf Robert B. , Brahmer Julie R. , Velculescu Victor E. , Zaidi Ali H. , Forde Patrick M. , Anagnostou Valsamo
Published: January 2024

Supplementary Fig.S5 Associations between ctDNA molecular responses and tumor PD-L1 expression levels. (A) Association
between PD-L1 expression and ctDNA molecular response in 24 patients with detectable ctDNA and evaluable PD-L1 expression, the subset of 8 patients who received chemo-immunotherapy combination treatments and (C) in 16 patients who received
immune checkpoint monotherapy. P values were assessed using the Fisher’s exact test. (D-E) Survival analyses following the
stratification of molecular response groups according to PD-L1 expression levels. Four molecular responders with cfTL
clearance across any sampled timepoint and low/negative (<50%) PD-L1 expression had superior PFS compared to molecular
responders with high (>50%) PD-L1 expression and molecular progressors (log-rank p = 0.006). Of these 4 patients, 3 received
first line pembro-chemotherapy combination regimens and 1 patient received first line pembrolizumab monotherapy. Differences
in OS were not significant between molecular response/PD-L1 expression groups (log-rank p = 0.135).
Figure S5 from Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Authors: Petronek Michael S. , Monga Varun , Bodeker Kellie L. , Kwofie Michael , Lee Chu-Yu , Mapuskar Kranti A. , Stolwijk Jeffrey M. , Zaher Amira , Wagner Brett A. , Smith Mark C. , Vollstedt Sandy , Brown Heather , Chandler Meghan L. , Lorack Amanda C. , Wulfekuhle Jared S. , Sarkaria Jann N. , Flynn Ryan T. , Greenlee Jeremy D.W. , Howard Matthew A. , Smith Brian J. , Jones Karra A. , Buettner Garry R. , Cullen Joseph J. , St-Aubin Joel , Buatti John M. , Magnotta Vincent A. , Spitz Douglas R. , Allen Bryan G.
Published: January 2024

U251 cells have lower basal levels of labile iron.
Supplementary Fig S2 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Authors: Orozco Johnnie J. , Vo Phuong T. , Gooley Ted A. , Haaf Robyn L. , Lundberg Sally J. , Hamlin Donald K. , Wilbur D. Scott , Matesan Manuela C. , Fisher Darrell R. , Gopal Ajay K. , Green Damian J. , Pagel John M. , Sandmaier Brenda M.
Published: January 2024

Supplementary Figure S2: Survival by disease burden at time of HCT
Figure S3 from Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Authors: Petronek Michael S. , Monga Varun , Bodeker Kellie L. , Kwofie Michael , Lee Chu-Yu , Mapuskar Kranti A. , Stolwijk Jeffrey M. , Zaher Amira , Wagner Brett A. , Smith Mark C. , Vollstedt Sandy , Brown Heather , Chandler Meghan L. , Lorack Amanda C. , Wulfekuhle Jared S. , Sarkaria Jann N. , Flynn Ryan T. , Greenlee Jeremy D.W. , Howard Matthew A. , Smith Brian J. , Jones Karra A. , Buettner Garry R. , Cullen Joseph J. , St-Aubin Joel , Buatti John M. , Magnotta Vincent A. , Spitz Douglas R. , Allen Bryan G.
Published: January 2024

Test, re-test study to determine inter- and intra-session variability of T2* mapping in vivo.
Supplementary Fig S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Authors: Orozco Johnnie J. , Vo Phuong T. , Gooley Ted A. , Haaf Robyn L. , Lundberg Sally J. , Hamlin Donald K. , Wilbur D. Scott , Matesan Manuela C. , Fisher Darrell R. , Gopal Ajay K. , Green Damian J. , Pagel John M. , Sandmaier Brenda M.
Published: January 2024

Supplementary Figure S1: Outline of Treatment Plan
Data from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Authors: Kesari Santosh , Wagle Naveed , Carrillo Jose A. , Sharma Akanksha , Nguyen Minhdan , Truong Judy , Gill Jaya M. , Nersesian Raffi , Nomura Natsuko , Rahbarlayegh Elnaz , Barkhoudarian Garni , Sivakumar Walavan , Kelly Daniel F. , Krauss Howard , Bustos Matias A. , Hoon Dave S.B. , Anker Lars , Singh Arun S. , Sankhala Kamalesh K. , Juarez Tiffany M.
Published: January 2024

AbstractPurpose:
Chordomas are ultrarare tumors of the axial spine and skull-base without approved systemic therapy. Most chordomas have negative expression of thymidylate synthase (TS), suggesting a potential for responding to the antifolate agent pemetrexed, which inhibits TS and other enzymes involved in nucleotide biosynthesis. We evaluated the therapeutic activity and safety of high-dose pemetrexed in progressive chordoma.
Patients and Methods:
Adult patients with previously treated, progressive chordoma participated in an open-label, single-institution, single-arm, pilot clinical trial of intravenous pemetrexed 900 mg/m2 every 3 weeks and supportive medications of folic acid, vitamin B12, and dexamethasone. The primary endpoint was objective response rate according to RECIST v1.1. Secondary endpoints included adverse events, progression-free survival (PFS), tumor molecular profiles, and alterations in tissue and blood-based biomarkers.
Results:
Fifteen patients were enrolled and the median number of doses administered was 15 (range, 4–31). One patient discontinued treatment due to psychosocial issues after four cycles and one contracted COVID-19 after 13 cycles. Of the 14 response-evaluable patients, 2 (14%) achieved a partial response and 10 (71%) demonstrated stable disease. Median PFS was 10.5 months (95% confidence interval: 9 months–undetermined) and 6-month PFS was 67%. Adverse events were expected and relatively mild, with one grade 3 creatinine increased, and one each of grade 3 and 4 lymphopenia. No grade 5 adverse events, unexpected toxicities, or dose-limiting toxicities were observed. Several patients reported clinical improvement in disease-related symptoms.
Conclusions:
High-dose pemetrexed appears tolerable and shows objective antitumor activity in patients with chordoma. Phase II studies of high-dose pemetrexed are warranted.
Data from Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma
Authors: Pan Minggui , Zhou Maggie Yuxi , Jiang Chen , Zhang Zheyang , Bui Nam Q. , Bien Jeffrey , Siy Amanda , Achacoso Ninah , Solorzano Aleyda V. , Tse Pamela , Chung Elaine , Thomas Sachdev , Habel Laurel A. , Ganjoo Kristen N.
Published: January 2024

AbstractPurpose:
To examine whether overall survival (OS) differs for male and female patients with advanced soft-tissue sarcoma (STS).
Experimental Design:
The study included patients from Kaiser Permanente Northern California and Stanford Cancer Center with grade 2 and 3 locally advanced or metastatic STS whose tumor underwent next-generation sequencing. We used Cox regression modeling to examine association of sex and OS adjusting for other important factors.
Results:
Among 388 eligible patients, 174 had leiomyosarcoma (LMS), 136 had undifferentiated pleomorphic sarcoma (UPS), and 78 had liposarcoma. OS for male versus female patients appeared to be slightly better among the full cohort [HR = 0.89; 95% confidence interval (CI), 0.66–1.20]; this association appeared to be stronger among the subsets of patients with LMS (HR = 0.76; 95% CI, 0.39–1.49) or liposarcoma (HR = 0.74; 95% CI, 0.32–1.70). Better OS for male versus female patients was also observed among all molecular subgroups except mutRB1 and mutATRX, especially among patients whose tumor retained wtTP53 (HR = 0.73; 95% CI, 0.44–1.18), wtCDKN2A (HR = 0.85; 95% CI, 0.59–1.23), wtRB1 (HR = 0.73; 95% CI, 0.51–1.04), and among patients whose tumor had mutPTEN (HR = 0.37; 95% CI, 0.09–1.62). OS also appeared to be better for males in the MSK-IMPACT and TCGA datasets.
Conclusions:
A fairly consistent pattern of apparent better OS for males across histologic and molecular subgroups of STS was observed. If confirmed, our results could have implications for clinical practice for prognostic stratification and possibly treatment tailoring as well as for future clinical trials design.
Data from Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colorectal Cancer
Authors: Li Jianxia , Hu Huabin , Qin Ge , Bai Fan , Wu Xianrui , Ke Haoxian , Zhang Jianwei , Xie Yuqian , Wu Zehua , Fu Yang , Zheng Hongbo , Gong Longlong , Xie Zhi , Deng Yanhong
Published: January 2024

AbstractPurpose:
Immune checkpoint inhibitors (ICI) have become the standard of care for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer. However, biomarkers of response to ICI are still lacking.
Experimental Design:
Forty-two patients with dMMR colorectal cancer treated with neoadjuvant PD-1 blockade were prospectively enrolled. To identify biomarkers of pathologic complete response (pCR) to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles based on next-generation sequencing, and immune cell density based on multiplex immunofluorescence (mIF) staining. An integrated analysis of single-cell RNA sequencing from our previous study and GSE178341, as well as mIF was performed to further explore the significance of the tumor microenvironment (TME) on pCR response.
Results:
The tumor mutation burden of both tumor tissue and plasma blood samples was comparable between the pCR and non-pCR groups, while HLA-DQA1 and HLA-DQB1 were significantly overexpressed in the pCR group. Gene signature enrichment analysis showed that pathways including T-cell receptor pathway, antigen presentation pathway were significantly enriched in the pCR group. In addition, higher pre-existing CD8+ T-cell density was associated with pCR response (767.47 per.mm2 vs. 326.64 per.mm2, P = 0.013 Wilcoxon test). Further integrated analysis showed that CD8+ T cells with low PD-1 expression (PD-1lo CD8+ T cells) expressing high levels of TRGC2, CD160, and KLRB1 and low levels of proliferated and exhausted genes were significantly associated with pCR response.
Conclusions:
Immune-associated transcriptomic features, particularly CD8+ T cells were associated with pCR response to ICI in dMMR colorectal cancer. Heterogeneity of TME within dMMR colorectal cancer may help to discriminate patients with complete response to neoadjuvant ICI.
Data from PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis
Authors: Hu Jia , Hameed Meera R. , Agaram Narasimhan P. , Whiting Karissa A. , Qin Li-Xuan , Villano Anthony M. , O'Connor Rachael B. , Rozenberg Julian M. , Cohen Sonia , Prendergast Katherine , Kryeziu Sara , White Richard L. , Posner Mitchell C. , Socci Nicholas D. , Gounder Mrinal M. , Singer Samuel , Crago Aimee M.
Published: January 2024

AbstractPurpose:
This study sought to identify β-catenin targets that regulate desmoid oncogenesis and determine whether external signaling pathways, particularly those inhibited by sorafenib (e.g., PDGFRβ), affect these targets to alter natural history or treatment response in patients.
Experimental Design:
In vitro experiments utilized primary desmoid cell lines to examine regulation of β-catenin targets. Relevance of results was assessed in vivo using Alliance trial A091105 correlative biopsies.
Results:
CTNNB1 knockdown inhibited hypoxia-regulated gene expression in vitro and reduced levels of HIF1α protein. ChIP-seq identified ABL1 as a β-catenin transcriptional target that modulated HIF1α and desmoid cell proliferation. Abrogation of either CTNNB1 or HIF1A inhibited desmoid cell–induced VEGFR2 phosphorylation and tube formation in endothelial cell co-cultures. Sorafenib inhibited this activity directly but also reduced HIF1α protein expression and c-Abl activity while inhibiting PDGFRβ signaling in desmoid cells. Conversely, c-Abl activity and desmoid cell proliferation were positively regulated by PDGF-BB. Reduction in PDGFRβ and c-Abl phosphorylation was commonly observed in biopsy samples from patients after treatment with sorafenib; markers of PDGFRβ/c-Abl pathway activation in baseline samples were associated with tumor progression in patients on the placebo arm and response to sorafenib in patients receiving treatment.
Conclusions:
The β-catenin transcriptional target ABL1 is necessary for proliferation and maintenance of HIF1α in desmoid cells. Regulation of c-Abl activity by PDGF signaling and targeted therapies modulates desmoid cell proliferation, thereby suggesting a reason for variable biologic behavior between tumors, a mechanism for sorafenib activity in desmoids, and markers predictive of outcome in patients.
Data from Phase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells
Authors: Ganju Vinod , Marx Gavin , Pattison Scott , Amaro-Mugridge Nancy B. , Zhao Jing-Ting , Williams Bryan R.G. , MacDiarmid Jennifer A. , Brahmbhatt Himanshu
Published: January 2024

AbstractPurpose:
We assessed the safety and efficacy of an EGFR-targeted, super-cytotoxic drug, PNU-159682-packaged nanocells with α-galactosyl ceramide-packaged nanocells (E-EDV-D682/GC) in patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had exhausted all treatment options.
Patients and Methods:
ENG9 was a first-in-man, single-arm, open-label, phase I/IIa, dose-escalation clinical trial. Eligible patients had advanced PDAC, Eastern Cooperative Oncology Group status 0 to 1, and failed all treatments. Primary endpoints were safety and overall survival (OS).
Results:
Of 25 enrolled patients, seven were withdrawn due to rapidly progressive disease and one patient withdrew consent. All 25 patients were assessed for toxicity, 24 patients were assessed for OS, which was also assessed for 17 patients completing one treatment cycle [evaluable subset (ES)]. Nineteen patients (76.0%) experienced at least one treatment-related adverse event (graded 1 to 2) resolving within hours. There were no safety concerns, dose reductions, patient withdrawal, or treatment-related deaths.

Median OS (mOS) was 4.4 months; however, mOS of the 17 ES patients was 6.9 months [208 days; range, 83–591 days; 95.0% confidence interval (CI), 5.6–10.3 months] and mOS of seven patients who did not complete one cycle was 1.8 months (54 days; range, 21–72; 95.0% CI, 1.2–2.2 months). Of the ES, 47.1% achieved stable disease and one partial response. Ten subjects in the ES survived over 6 months, the longest 19.7 months. During treatments, 82.0% of the ES maintained stable weight.
Conclusions:
E-EDV-D682/GC provided significant OS, minimal side effects, and weight stabilization in patients with advanced PDAC. Advanced PDAC can be safely treated with super-cytotoxic drugs via EnGeneIC Dream Vectors to overcome multidrug resistance.
Data from Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Authors: Ou Xiaomin , Zhai Ruiping , Wei Wenjun , Chen Jiaying , Ou Dan , Liao Tian , Xu Tingting , Zhu Yongxue , Wang Yulong , Huang Shenglin , Shi Rongliang , Wu Bin , Chen Tongzhen , Li Yuan , Yang Zhongyi , Zhou Changming , Liu Yuan , Jiang Ziting , Zeng Min , Liu Xin , Ji Dongmei , Ying Hongmei , Zhang Zhen , Hu Chaosu , Lu Xueguan , Ji Qinghai , He Xiayun , Wang Yu
Published: January 2024

AbstractPurpose:
The aim of this study was to assess the efficacy, toxicities, and potential role of larynx preservation of induction chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitor in locally advanced laryngeal and hypopharyngeal cancer.
Patients and Methods:
This is a single-arm phase II study. Patients with histopathologically confirmed, resectable locally advanced laryngeal/hypopharyngeal squamous cell carcinoma and Eastern Cooperative Oncology Group Performance Status 0–1 were eligible. Three cycles of induction chemotherapy (paclitaxel 175 mg/m2 d1, cisplatin 25 mg/m2 d1–3) combined with PD-1 inhibitor (toripalimab 240 mg d0) were administered. Response assessment was performed after induction chemoimmunotherapy using RECIST 1.1 criteria. Patients with a complete/partial response of the primary tumor received concurrent chemoradiation, followed by maintenance therapy of toripalimab. Otherwise, patients were referred to surgery, followed by adjuvant (chemo) radiation and maintenance therapy of toripalimab. The primary endpoint is a larynx preservation rate at 3 months postradiation.
Results:
Twenty-seven patients were enrolled. Most cases exhibited stage IV disease (81.5%), with T4 representing 37.0%. Five patients underwent pretreatment tracheostomy because of impaired larynx function. Overall response rate of induction chemoimmunotherapy was 85.2%. At 3 months postradiation, the larynx preservation rate was 88.9%. With a median follow-up of 18.7 months, the 1-year overall survival rate, progression-free survival rate, and larynx preservation rate were 84.7%, 77.6%, and 88.7%, respectively. When excluding those with pretreatment tracheostomy, the 1-year larynx preservation rate was 95.5%. Exploratory analysis revealed that relapse correlated with enrichment of RNA signature of hypoxia and M2 macrophage–associated genes.
Conclusions:
Induction toripalimab combined with chemotherapy provided encouraging activity, promising larynx preservation rate and acceptable toxicity in this cohort of extensively locally advanced laryngeal and hypopharyngeal cancer.
Data from Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Authors: Mehanna Hisham , Rapozo Davy , von Zeidler Sandra V. , Harrington Kevin J. , Winter Stuart C. , Hartley Andrew , Nankivell Paul , Schache Andrew G. , Sloan Philip , Odell Edward W. , Thavaraj Selvam , Hunter Keith D. , Shah Ketan A. , Thomas Gareth J. , Long Anna , Amel-Kashipaz Rasoul , Brown Rachel M. , Conn Brendan , Hall Gillian L. , Matthews Paul , Weir Justin , Yeo Yen , Pring Miranda , West Catharine M.L. , McCaul James , Golusinski Pawel , Sitch Alice , Spruce Rachel , Batis Nikolaos , Bryant Jennifer L. , Brooks Jill M. , Jones Terence M. , Buffa Francesca , Haider Syed , Robinson Max
Published: January 2024

AbstractPurpose:
While there are several prognostic classifiers, to date, there are no validated predictive models that inform treatment selection for oropharyngeal squamous cell carcinoma (OPSCC).

Our aim was to develop clinical and/or biomarker predictive models for patient outcome and treatment escalation for OPSCC.
Experimental Design:
We retrospectively collated clinical data and samples from a consecutive cohort of OPSCC cases treated with curative intent at ten secondary care centers in United Kingdom and Poland between 1999 and 2012. We constructed tissue microarrays, which were stained and scored for 10 biomarkers. We then undertook multivariable regression of eight clinical parameters and 10 biomarkers on a development cohort of 600 patients. Models were validated on an independent, retrospectively collected, 385-patient cohort.
Results:
A total of 985 subjects (median follow-up 5.03 years, range: 4.73–5.21 years) were included. The final biomarker classifier, comprising p16 and survivin immunohistochemistry, high-risk human papillomavirus (HPV) DNA in situ hybridization, and tumor-infiltrating lymphocytes, predicted benefit from combined surgery + adjuvant chemo/radiotherapy over primary chemoradiotherapy in the high-risk group [3-year overall survival (OS) 63.1% vs. 41.1%, respectively, HR = 0.32; 95% confidence interval (CI), 0.16–0.65; P = 0.002], but not in the low-risk group (HR = 0.4; 95% CI, 0.14–1.24; P = 0.114). On further adjustment by propensity scores, the adjusted HR in the high-risk group was 0.34, 95% CI = 0.17–0.67, P = 0.002, and in the low-risk group HR was 0.5, 95% CI = 0.1–2.38, P = 0.384. The concordance index was 0.73.
Conclusions:
We have developed a prognostic classifier, which also appears to demonstrate moderate predictive ability. External validation in a prospective setting is now underway to confirm this and prepare for clinical adoption.
Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer
Authors: Cescon David W. , Hilton John , Morales Murilo Serafin , Layman Rachel M. , Pluard Timothy , Yeo Belinda , Park In Hae , Provencher Louise , Kim Sung-Bae , Im Young-Hyuck , Wyce Anastasia , Krishnatry Anu Shilpa , Hicks Kirsty , Zhang Qu , Barbash Olena , Khaled Ahmed , Horner Thierry , Dhar Arindam , Oliveira Mafalda , Sparano Joseph A.
Published: January 2024

AbstractPurpose:
Endocrine-based therapy is the initial primary treatment option for hormone receptor–positive and human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC). However, patients eventually experience disease progression due to resistance to endocrine therapy. Molibresib (GSK525762) is a small-molecule inhibitor of bromodomain and extraterminal (BET) family proteins (BRD2, BRD3, BRD4, and BRDT). Preclinical data suggested that the combination of molibresib with endocrine therapy might overcome endocrine resistance. This study aimed to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy [objective response rate (ORR)] of molibresib combined with fulvestrant in women with HR+/HER2− mBC.
Patients and Methods:
In this phase I/II dose-escalation and dose-expansion study, patients received oral molibresib 60 or 80 mg once daily in combination with intramuscular fulvestrant. Patients enrolled had relapsed/refractory, advanced/metastatic HR+/HER2− breast cancer with disease progression on prior treatment with an aromatase inhibitor, with or without a cyclin-dependent kinase 4/6 inhibitor.
Results:
The study included 123 patients. The most common treatment-related adverse events (AE) were nausea (52%), dysgeusia (49%), and fatigue (45%). At a 60-mg dosage of molibresib, >90% of patients experienced treatment-related AE. Grade 3 or 4 treatment-related AE were observed in 47% and 48% of patients treated with molibresib 60 mg and molibresib 80 mg, respectively. The ORR was 13% [95% confidence interval (CI), 8–20], not meeting the 25% threshold for proceeding to phase II. Among 82 patients with detected circulating tumor DNA and clinical outcome at study enrollment, a strong association was observed between the detection of copy-number amplification and poor progression-free survival (HR, 2.89; 95% CI, 1.73–4.83; P < 0.0001).
Conclusions:
Molibresib in combination with fulvestrant did not demonstrate clinically meaningful activity in this study.
Data from Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Authors: Petronek Michael S. , Monga Varun , Bodeker Kellie L. , Kwofie Michael , Lee Chu-Yu , Mapuskar Kranti A. , Stolwijk Jeffrey M. , Zaher Amira , Wagner Brett A. , Smith Mark C. , Vollstedt Sandy , Brown Heather , Chandler Meghan L. , Lorack Amanda C. , Wulfekuhle Jared S. , Sarkaria Jann N. , Flynn Ryan T. , Greenlee Jeremy D.W. , Howard Matthew A. , Smith Brian J. , Jones Karra A. , Buettner Garry R. , Cullen Joseph J. , St-Aubin Joel , Buatti John M. , Magnotta Vincent A. , Spitz Douglas R. , Allen Bryan G.
Published: January 2024

AbstractPurpose:
Pharmacologic ascorbate (P-AscH−) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH− with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T2* mapping to predict GBM response to P-AscH− in humans.
Patients and Methods:
The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T2*-based MRI to assess its utility as an Fe-dependent biomarker.
Results:
Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T2* relaxation < 50 ms were associated with a significant increase in PFS compared with T2*-high subjects (11.2 months vs. 5.7 months, P < 0.05) and a trend toward increased OS (26.5 months vs. 17.5 months). These results were validated in preclinical in vitro and in vivo model systems.
Conclusions:
P-AscH− combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes.

See related commentary by Nabavizadeh and Bagley, p. 255
Data from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors
Authors: Orozco Johnnie J. , Vo Phuong T. , Gooley Ted A. , Haaf Robyn L. , Lundberg Sally J. , Hamlin Donald K. , Wilbur D. Scott , Matesan Manuela C. , Fisher Darrell R. , Gopal Ajay K. , Green Damian J. , Pagel John M. , Sandmaier Brenda M.
Published: January 2024

AbstractPurpose:
Hematopoietic cell transplantation (HCT) has curative potential for myeloid malignancies, though many patients cannot tolerate myeloablative conditioning with high-dose chemotherapy alone or with total-body irradiation (TBI). Here we report long-term outcomes from a phase I/II study using iodine-131 (131I)-anti-CD45 antibody BC8 combined with nonmyeloablative conditioning prior to HLA-haploidentical HCT in adults with high-risk relapsed/ refractory acute myeloid or lymphoid leukemia (AML or ALL), or myelodysplastic syndrome (MDS; ClinicalTrials.gov, NCT00589316).
Patients and Methods:
Patients received a tracer diagnostic dose before a therapeutic infusion of 131I­anti-CD45 to deliver escalating doses (12–26 Gy) to the dose-limiting organ. Patients subsequently received fludarabine, cyclophosphamide (CY), and 2 Gy TBI conditioning before haploidentical marrow HCT. GVHD prophylaxis was posttransplant CY plus tacrolimus and mycophenolate mofetil.
Results:
Twenty-five patients (20 with AML, 4 ALL and 1 high-risk MDS) were treated; 8 had ≥ 5% blasts by morphology (range 9%–20%), and 7 had previously failed HCT. All 25 patients achieved a morphologic remission 28 days after HCT, with only 2 patients showing minimal residual disease (0.002–1.8%) by flow cytometry. Median time to engraftment was 15 days for neutrophils and 23 days for platelets. Point estimates for overall survival and progression-free survival were 40% and 32% at 1 year, and 24% at 2 years, respectively. Point estimates of relapse and nonrelapse mortality at 1 year were 56% and 12%, respectively.
Conclusions:
131I-anti-CD45 radioimmunotherapy prior to haploidentical HCT is feasible and can be curative in some patients, including those with disease, without additional toxicity.
Data from Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Authors: Lerner Seth P. , McConkey David J. , Tangen Catherine M. , Meeks Joshua J. , Flaig Thomas W. , Hua Xing , Daneshmand Siamak , Alva Ajjai Shivaram , Lucia M. Scott , Theodorescu Dan , Goldkorn Amir , Milowsky Matthew I. , Choi Woonyoung , Bangs Rick , Gustafson Daniel L. , Plets Melissa , Thompson Ian M.
Published: January 2024

AbstractPurpose:
The Coexpression Extrapolation (COXEN) gene expression model with chemotherapy-specific scores [for methotrexate, vinblastine, adriamycin, cisplatin (ddMVAC) and gemcitabine/cisplatin (GC)] was developed to identify responders to neoadjuvant chemotherapy (NAC). We investigated RNA-based molecular subtypes as additional predictive biomarkers for NAC response, progression-free survival (PFS), and overall survival (OS) in patients treated in S1314.
Experimental Design:
A total of 237 patients were randomized between four cycles of ddMVAC (51%) and GC (49%). On the basis of Affymetrix transcriptomic data, we determined subtypes using three classifiers: TCGA (k = 5), Consensus (k = 6), and MD Anderson (MDA; k = 3) and assessed subtype association with path response to NAC and determined associations with COXEN. We also tested whether each classifier contributed additional predictive power when added to a model based on predefined stratification (strat) factors (PS 0 vs. 1; T2 vs. T3, T4a).
Results:
A total of 155 patients had gene expression results, received at least three of four cycles of NAC, and had pT-N response based on radical cystectomy. TCGA three-group classifier basal-squamous (BS)/neuronal, luminal (Lum), Lum infiltrated, and GC COXEN score yielded the largest AUCs for pT0 (0.59, P = 0.28; 0.60, P = 0.18, respectively). For downstaging (P = 0.10). The MDA classifier AUC was 0.63 (P = 0.18) and the GC COXEN score AUC was 0.62 (P = 0.23), but neither significantly improved the AUC. There was no statistically significant association of stratification factors and subtypes with PFS or OS.
Conclusions:
The Consensus classifier, based in part on the TCGA and MDA classifiers, modestly improved prediction for pathologic downstaging but subtypes were not associated with PFS or OS.
Supplementary File 3 from WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers
Authors: Sottnik Joseph L. , Shackleford Madeleine T. , Robinson Sydney K. , Villagomez Fabian R. , Bahnassy Shaymaa , Oesterreich Steffi , Hu Junxiao , Madak-Erdogan Zeynep , Riggins Rebecca B. , Corr Bradley R. , Cook Linda S. , Treviño Lindsey S. , Bitler Benjamin G. , Sikora Matthew J.
Published: January 2024

Metabolomics datasets and siRNA analyses
Supplementary File 2 from WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers
Authors: Sottnik Joseph L. , Shackleford Madeleine T. , Robinson Sydney K. , Villagomez Fabian R. , Bahnassy Shaymaa , Oesterreich Steffi , Hu Junxiao , Madak-Erdogan Zeynep , Riggins Rebecca B. , Corr Bradley R. , Cook Linda S. , Treviño Lindsey S. , Bitler Benjamin G. , Sikora Matthew J.
Published: January 2024

BioID analyses
Supplemental Methods 1 from WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers
Authors: Sottnik Joseph L. , Shackleford Madeleine T. , Robinson Sydney K. , Villagomez Fabian R. , Bahnassy Shaymaa , Oesterreich Steffi , Hu Junxiao , Madak-Erdogan Zeynep , Riggins Rebecca B. , Corr Bradley R. , Cook Linda S. , Treviño Lindsey S. , Bitler Benjamin G. , Sikora Matthew J.
Published: January 2024

Mass spectrometry methods supplement
Supplemental Figure 2 from WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers
Authors: Sottnik Joseph L. , Shackleford Madeleine T. , Robinson Sydney K. , Villagomez Fabian R. , Bahnassy Shaymaa , Oesterreich Steffi , Hu Junxiao , Madak-Erdogan Zeynep , Riggins Rebecca B. , Corr Bradley R. , Cook Linda S. , Treviño Lindsey S. , Bitler Benjamin G. , Sikora Matthew J.
Published: January 2024

RPPA dataset clustering
Supplemental Figure 1 from WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers
Authors: Sottnik Joseph L. , Shackleford Madeleine T. , Robinson Sydney K. , Villagomez Fabian R. , Bahnassy Shaymaa , Oesterreich Steffi , Hu Junxiao , Madak-Erdogan Zeynep , Riggins Rebecca B. , Corr Bradley R. , Cook Linda S. , Treviño Lindsey S. , Bitler Benjamin G. , Sikora Matthew J.
Published: January 2024

BioID setup and proof-of-concept